Literature DB >> 15678794

Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design.

Bart A N Verhoeven1, Evelyn Velema, Arjan H Schoneveld, Jean Paul P M de Vries, Peter de Bruin, Cees A Seldenrijk, Dominique P V de Kleijn, Els Busser, Yolande van der Graaf, Frans Moll, Gerard Pasterkamp.   

Abstract

In clinical practice, biological markers are not available to routinely assess the progression of atherosclerotic disease or the development of restenosis following endarterectomy or catheter based interventions. Endarterectomy procedures provide an opportunity to study mechanisms of restenosis and progression of atherosclerotic disease since atherosclerotic tissue is obtained. Athero-Express is an ongoing prospective study, initiated in 2002, with the objective to investigate the etiological value of plaque characteristics for long term outcome. Patients are included who undergo an endarterectomy of the carotid artery. At baseline blood is withdrawn, patients fill in an extensive questionnaire and diagnostic examinations are performed. Atherosclerotic plaques are freshly harvested, immunohistochemically stained and examined for the presence of macrophages, smooth muscle cells, collagen and fat. Parts of the atherosclerotic plaques are freshly frozen to study protease activity and protein and RNA expressions. Patients undergo a duplex follow up to assess procedural restenosis (primary endpoint) at 3 months, 1 year and 2 years. Secondary endpoints encompass major adverse cardiovascular events. In the future, the creation of this biobank with atherosclerotic specimen will allow the design of cross-sectional and follow up studies with the objective to investigate the expression of newly discovered genes and proteins and their interaction with patients and plaque characteristics in the progression of atherosclerotic disease. Objective is to include 1000-1200 patients in 5 years. In January 2004, 289 patients had been included. It is expected that 250 patients will be included yearly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15678794     DOI: 10.1007/s10564-004-2304-6

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  25 in total

1.  Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis.

Authors:  G S Roubin; G New; S S Iyer; J J Vitek; N Al-Mubarak; M W Liu; J Yadav; C Gomez; R E Kuntz
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

2.  Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial.

Authors: 
Journal:  Lancet       Date:  2001-06-02       Impact factor: 79.321

3.  Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study.

Authors:  T Mannami; M Konishi; S Baba; N Nishi; A Terao
Journal:  Stroke       Date:  1997-03       Impact factor: 7.914

4.  Carotid artery stenosis in patients with peripheral arterial disease: the SMART study. SMART study group.

Authors:  P C Simons; A Algra; B C Eikelboom; D E Grobbee; Y van der Graaf
Journal:  J Vasc Surg       Date:  1999-09       Impact factor: 4.268

5.  Watershed infarcts in the brain caused by microemboli.

Authors:  A Torvik; K Skullerud
Journal:  Clin Neuropathol       Date:  1982       Impact factor: 1.368

6.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

7.  Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.

Authors:  John Robert Crouse; Diederick E Grobbee; Daniel H O'Leary; Michiel L Bots; Gregory W Evans; Mike K Palmer; Ward A Riley; Joel S Raichlen
Journal:  Cardiovasc Drugs Ther       Date:  2004-05       Impact factor: 3.727

8.  Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.

Authors:  H J M Barnett; D W Taylor; R B Haynes; D L Sackett; S J Peerless; G G Ferguson; A J Fox; R N Rankin; V C Hachinski; D O Wiebers; M Eliasziw
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

9.  Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.

Authors:  Claudia Stöllberger; Pavel Chnupa; Christine Abzieher; Thomas Länger; Josef Finsterer; Igor Klem; Elisabeth Hartl; Cornelius Wehinger; Barbara Schneider
Journal:  Clin Cardiol       Date:  2004-01       Impact factor: 2.882

10.  Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention.

Authors:  Braim M Rahel; Frank L J Visseren; Maarten-Jan Suttorp; Thijs H W Plokker; Johannes C Kelder; Bartelt M de Jongh; K Paul Bouter; Rob J A Diepersloot
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

View more
  42 in total

1.  Common coding variant in SERPINA1 increases the risk for large artery stroke.

Authors:  Rainer Malik; Therese Dau; Maria Gonik; Anirudh Sivakumar; Daniel J Deredge; Evgeniia V Edeleva; Jessica Götzfried; Sander W van der Laan; Gerard Pasterkamp; Nathalie Beaufort; Susana Seixas; Steve Bevan; Lisa F Lincz; Elizabeth G Holliday; Annette I Burgess; Kristiina Rannikmäe; Jens Minnerup; Jennifer Kriebel; Melanie Waldenberger; Martina Müller-Nurasyid; Peter Lichtner; Danish Saleheen; Peter M Rothwell; Christopher Levi; John Attia; Cathie L M Sudlow; Dieter Braun; Hugh S Markus; Patrick L Wintrode; Klaus Berger; Dieter E Jenne; Martin Dichgans
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

Review 2.  Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease.

Authors:  Gerard Pasterkamp; Hester M den Ruijter; Peter Libby
Journal:  Nat Rev Cardiol       Date:  2016-10-20       Impact factor: 32.419

3.  10-years experience with the Athero-Express study.

Authors:  Willem E Hellings; Frans L Moll; Dominique P V de Kleijn; Gerard Pasterkamp
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

4.  Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages.

Authors:  Jason L Johnson; Graciela B Sala-Newby; Yasmin Ismail; Concepción M Aguilera; Andrew C Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

5.  Matrix Gla Protein, Plaque Stability, and Cardiovascular Events in Patients with Severe Atherosclerotic Disease.

Authors:  Sabine R Zwakenberg; Yvonne T van der Schouw; Cees Vermeer; Gerard Pasterkamp; Hester M den Ruijter; Joline W J Beulens
Journal:  Cardiology       Date:  2018-10-10       Impact factor: 1.869

6.  Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study.

Authors:  Imo E Hoefer; Jan-Willem Sels; J Wouter Jukema; Sandrin Bergheanu; Erik Biessen; Elizabeth McClellan; Mat Daemen; Pieter Doevendans; Philip de Groot; Marieke Hillaert; Sebastiaan Horsman; Mustafa Ilhan; Johan Kuiper; Nico Pijls; Ken Redekop; Peter van der Spek; Andrew Stubbs; Eric van de Veer; Johannes Waltenberger; Anton-Jan van Zonneveld; Gerard Pasterkamp
Journal:  Clin Res Cardiol       Date:  2013-08-23       Impact factor: 5.460

7.  Symptomatic carotid atherosclerotic disease: correlations between plaque composition and ipsilateral stroke risk.

Authors:  Dominic Pj Howard; Guus W van Lammeren; Peter M Rothwell; Jessica N Redgrave; Frans L Moll; Jean-Paul Pm de Vries; Dominique Pv de Kleijn; Hester M den Ruijter; Gert Jan de Borst; Gerard Pasterkamp
Journal:  Stroke       Date:  2014-12-04       Impact factor: 7.914

8.  Sex-Stratified Gene Regulatory Networks Reveal Female Key Driver Genes of Atherosclerosis Involved in Smooth Muscle Cell Phenotype Switching.

Authors:  Johan L M Björkegren; Hester M den Ruijter; Robin J G Hartman; Katie Owsiany; Lijiang Ma; Simon Koplev; Ke Hao; Lotte Slenders; Mete Civelek; Michal Mokry; Jason C Kovacic; Gerard Pasterkamp; Gary Owens
Journal:  Circulation       Date:  2021-01-27       Impact factor: 29.690

9.  Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis.

Authors:  Soraya Taleb; Mélissa Romain; Bhama Ramkhelawon; Catherine Uyttenhove; Gerard Pasterkamp; Olivier Herbin; Bruno Esposito; Nicolas Perez; Hideo Yasukawa; Jacques Van Snick; Akihiko Yoshimura; Alain Tedgui; Ziad Mallat
Journal:  J Exp Med       Date:  2009-09-08       Impact factor: 14.307

10.  Atherosclerosis: from biology to pharmacological treatment.

Authors:  Graziano Riccioni; Valeriana Sblendorio
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.